In highly metastatic basal-like MDA-MB-231 breast cancer cells, our group has shown that metformin treatment dynamically suppresses the CD44+/CD24−/low CSC phenotype via transcriptional repression of the EMT machinery including Transforming Growth Factor-β1, ZEB, TWIST and SLUG (SNAIL2) [149]. Here, CD44 is linked to breast carcinoma.